Журнал включен в российские и международные библиотечные и реферативные базы данных
РИНЦ (Россия)
RINZ (RUSSIA)
Регистрационное агентство DOI (США)
DOI Registration Agency (USA)
Эко-Вектор (Россия)
Eco-Vector (Russia)
Ulrichsweb (Ulrich’s Periodicals Director

The use of modern macrolides in the treatment of diseases of the respiratory system

DOI: https://doi.org/10.29296/25879979-2022-06-08
Download full text PDF
Issue: 
6
Year: 
2022

V.V. Skvortsov, I.V. Rodionova, F.Z. Tagiev, S.S. Baymankulov
Federal State Budgetary Educational Institution of Higher Education «Volgograd state medical university» of the ministry of health of the Russian Federation, e-mail: [email protected]

One of the principles of effective treatment of infectious and inflammatory diseases is rational antibiotic therapy. The classical requirements for an antimicrobial drug are the prescription of the drug in strict accordance with the antibiotic sensitivity of the pathogen, safety, ease of use, pharmacoeconomical parameters. Over the past decade, there has been an increase in the resistance of pathogens to the most commonly used antibiotics, primarily to b-lactams, and an increase in the importance of atypical pathogens in the structure of infectious diseases. The frequency of undesirable side effects of antibiotics is also increasing, and b-lactams, primarily penicillins, are also leading here. The above reasons led to the renaissance of macrolides and to the widespread use of these drugs in outpatient practice. One of the most significant macrolides is azithromycin, which is among the most widely used antimicrobial agents in the world.
Keywords: 
azithromycin
COPD
bronchiectasis
cystic fibrosis
panbronchiolitis.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Strachunsky L.S., Kozlov S.N. Macrolides in modern clinical practice. Smolensk State Medical Academy, 2015: 232.
  2. Kozlov R.S., Veselov A.V. Macrolides and ketolides. In: Community-acquired respiratory tract infections: diagnosis and treatment. M., 2015: 49-65.
  3. Reshedko G.K., Kozlov R.S. The state of resistance to anti-infectious chemotherapy drugs in Russia. In the book: Practical Guide to anti-infective chemotherapy. Ed. L.S. Strachunsky, Y.B. Belousova, S.I. Kozlov. M., 2010: 32-47
  4. Schito G, Debbia E, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander project. J Antimicrob Chemother 2016; 46 (1): 3-9.
  5. The use of macrolide antibiotics in clinical practice. Methodological recommendations. Under the general editorship of A.L. Vertkin. M. 2000.
  6. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (eds.). New York, etc., 2016; 51-60.
  7. Rachina S.A., Sinopalnikov A.I. Infectious diseases of the lower respiratory tract. In: Fundamentals of Internal Medicine. Ed. V.S. Moiseev, J.D. Kobalava, I.V. Mayev et al. 2nd ed., reprint. and additional M.: LLC «MIA», 2020. Vol. 1. pp. 147 - 171.
  8. Hand V.L., Hand D.L. Mechanisms of accumulation and release of azithromycin in human polymorphonuclear leukocytes. Antibiotic. and chemother. 2002; 47 (7): 6-12.
  9. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2017; 125: 41-51.
  10. Treadway G, Pontani D. Paediatric savety of azithromycin: world- wide experience. J Antimicrob Chemother 2016; 37 (suppl. C): 143-9.
  11. Ioannidis J, Contopoulos-Ioannidis D, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for
  12. upper respiratory tractinfections. J Antimicrob Chemoter 2015; 48:
  13. 677-89.
  14. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs, 2017; 63: 2169-84.
  15. Practical guide to anti-infective chemotherapy edited by L.S. Strachunsky, Y.B. Belousov, S.N. Kozlov, M. 2007
  16. Li H, Zhou Y, Fan F et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. In- tern Med 2011; 50 (16): 1663–9.
  17. Cystic fibrosis (clinical picture, diagnosis, treatment, rehabilitation, medical examination): textbook for doctors / A.V. Orlov, O. I. Simonova, E. A. Roslavtseva, D. I. Shadrin. - St. Petersburg: Publishing House of I. I. Mechnikov NWSMU, 2014. - 160 p.: ill.
  18. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011; 12: CD002203.
  19. Vlasova A.V., Asherova I.K. The effect of long-term azithromycin therapy in a sub-inhibitory dose on the development of recurrent exacerbations of chronic bronchitis, indicators of respiratory function, nutritional status and microbiological spectrum of sputum in children with cystic fibrosis for two years. VII National Congress on Cystic Fibrosis. Voronezh, April 5-6, 2005.
  20. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365 (8): 689–98.
  21. Pomares X, Montón C, Espasa M et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 2011; 6: 449–56.
  22. Blasi F, Bonardi D, Aliberti S et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010; 23 (3): 200–7.
  23. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004; 59: 540–1.
  24. Cymbala AA, Edmonds LC, Bauer MA et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4 (2): 117–22.
  25. Anwar GA, Bourke S. C, Afolabi G et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102 (10): 1494–6.